|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.745 USD | +12.98% |
|
-9.10% | +6.39% |
| Apr. 18 | Health Care Flat on Rotation From Rate-Sensitive Sectors -- Health Care Roundup | DJ |
| Apr. 18 | Ocular Therapeutix Reports Positive Topline Data in Diabetic Retinopathy Trial; Shares Fall | MT |
Ocular Therapeutix, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported revenue was USD 58.44 million compared to USD 51.49 million a year ago. Net loss was USD 80.74 million compared to USD 71.04 million a year ago.
Basic loss per share from continuing operations was USD 1.01 compared to USD 0.92 a year ago. Diluted loss per share from continuing operations was USD 1.02 compared to USD 0.97 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| +6.39% | 734M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
OCULAR THERAPEUTIX, INC. 
